SCHEMBL5458048

SCHEMBL5458048

CC(=O)N1CCc2c(sc(NC(=O)C3CC3)c2C(N)=O)C1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.89
MEN1 O00255 3/20 0.89
ALDH1A1 P00352 5/20 0.78
KDM4E B2RXH2 4/20 0.78
GAA P10253 1/20 0.78
HSD17B10 Q99714 1/20 0.78
L3MBTL1 Q9Y468 1/20 0.73
CLK1 P49759 1/20 0.68
REV1 Q9UBZ9 3/20 0.67
HPGD P15428 3/20 0.64
FLT3 P36888 1/20 0.62
TNNI3 P19429 1/20 0.60
TNNT2 P45379 1/20 0.60
TNNC1 P63316 1/20 0.60
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
TSHR P16473 1/20 0.56
HTT P42858 1/20 0.56
CASP6 P55212 1/20 0.56
RXFP1 Q9HBX9 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447691 0.86 MEN1 (0.68) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL8289859 0.86 MEN1 (0.68) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL5453585 0.86 KMT2A (0.67) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL5467649 0.77 FLT3 (0.94) KMT2AMEN1ALDH1A1KDM4EHSD17B10
SCHEMBL3922474 0.77 FLT3 (1.00) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL5455726 0.76 FLT3 (0.97) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL8288845 0.76 FLT3 (0.97) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL3916303 0.76 REV1 (0.79) KMT2AMEN1ALDH1A1KDM4EHSD17B10
SCHEMBL5444948 0.74 FLT3 (0.70) KMT2AMEN1ALDH1A1KDM4EHSD17B10
SCHEMBL5451302 0.74 FLT3 (0.70) KMT2AMEN1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885MEN1 2891/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.